kras mutation and glutathion KRAS-targeted therapies in cancer: novel approaches overcoming resistance KRAS | OriGene Technologies Inc.
KRAS OriGene Technologies Inc. Rerouting the drug response: Overcoming metabolic adaptation in KRAS mutant cancers Science Signaling Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt Tanaka 2025 Cancer Science Wiley Online Library KRAS Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions PMC
Pay in 4 interest-free payments of $6.69 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



